Apim Therapeutics is a company headquartered in Norway.
Apim Therapeutics is a clinical-stage oncology company developing first-in-class PCNA-targeting peptide therapeutics to disrupt cellular stress responses and overcome cancer treatment resistance, with its lead candidate ATX-101 currently in clinical trials.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.